PFM Health Sciences’s Puma Biotechnology PBYI Stock Holding History

PFM Health Sciences’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-309,100	Closed	-$27M	–	102
2017 Q2	$27M	Buy	+309,100	New	+$17.3M	0.73%	48

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PFM Health Sciences's PBYI Position: Q4 2019 in Review

PFM Health Sciences sold out of Puma Biotechnology (PBYI) in Q4 2019, closing a stake of 3,689,538 shares — an estimated $39.7M sold.

PFM Health Sciences first reported a position in PBYI in Q2 2016 and held it in 12 quarters. The position peaked at $180M in Q4 2017. 133 funds tracked by Wall St. Rank hold PBYI as of Q4 2019.

PFM Health Sciences reported no remaining Puma Biotechnology position as of Q4 2019 after selling out during the quarter.
PFM Health Sciences sold 3,689,538 Puma Biotechnology shares in Q4 2019, an estimated $39.7M.
PFM Health Sciences first reported a position in Puma Biotechnology in Q2 2016 and held it in 12 quarters.
PFM Health Sciences's Puma Biotechnology position peaked at $180M in Q4 2017.
133 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2019.

Based on PFM Health Sciences's 13F filing for Q4 2019, filed 14 Feb 2020.